We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Multiple pathways of type 1 interferon production in lupus: the case for amlexanox.
- Authors
Todd, Ian; Thomas, Rhema E; Watt, Baltina D; Sutherland, Lissa; Afriyie-Asante, Afrakoma; Deb, Bishnu; Joseph, Blessy; Tighe, Patrick J; Lanyon, Peter; Fairclough, Lucy C
- Abstract
In the article, the author discusses the potential of the signaling molecule TANK-binding kinase 1 (TBK-1) inhibitors as therapeutic agents for systemic lupus erythematosus (SLE) by presenting the case of amlexanox, a topical drug for aphthous ulcer treatment. The drug was found to inhibit the IkB kinase TBK-1. Also cited are the effects of amlexanox on the TBK-1 activation pathways involving mitochondrial antiviral signaling (MAVS) and retinoic acid-inducible gene 1 (RIG-1).
- Subjects
AMINOPYRIDINES; CELL culture; CELL lines; CELLULAR signal transduction; INTERFERONS; LIGANDS (Biochemistry); MONOCLONAL antibodies; SYSTEMIC lupus erythematosus; TOLL-like receptors
- Publication
Rheumatology, 2020, Vol 59, Issue 12, p3980
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/keaa469